NASDAQ:TCON TRACON Pharmaceuticals (TCON) Stock Price, News & Analysis → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free TCON Stock Alerts $1.43 -0.10 (-6.54%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$1.42▼$1.5850-Day Range$1.43▼$12.6252-Week Range$1.42▼$14.75Volume119,416 shsAverage Volume192,656 shsMarket Capitalization$3.83 millionP/E Ratio2.13Dividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get TRACON Pharmaceuticals alerts: Email Address TRACON Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside4,095.8% Upside$60.00 Price TargetShort InterestBearish7.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.01Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($4.00) to ($5.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 stars 3.3 Analyst's Opinion Consensus RatingTRACON Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTRACON Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about TRACON Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.29% of the float of TRACON Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTRACON Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TRACON Pharmaceuticals has recently increased by 527.05%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTRACON Pharmaceuticals does not currently pay a dividend.Dividend GrowthTRACON Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCON. Previous Next 1.7 News and Social Media Coverage News SentimentTRACON Pharmaceuticals has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for TRACON Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 15 people have searched for TCON on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TRACON Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.61% of the stock of TRACON Pharmaceuticals is held by institutions.Read more about TRACON Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for TRACON Pharmaceuticals are expected to decrease in the coming year, from ($4.00) to ($5.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TRACON Pharmaceuticals is 2.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.23.Price to Earnings Ratio vs. SectorThe P/E ratio of TRACON Pharmaceuticals is 2.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 180.28.Read more about TRACON Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About TRACON Pharmaceuticals Stock (NASDAQ:TCON)TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.Read More TCON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCON Stock News HeadlinesMay 18 at 3:50 AM | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Lowered to Hold at StockNews.comMay 15 at 8:41 AM | msn.comTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call TranscriptMay 15 at 8:41 AM | finance.yahoo.comQ1 2024 TRACON Pharmaceuticals Inc Earnings CallMay 15 at 3:41 AM | finance.yahoo.comTRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | investorplace.comTCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024May 14, 2024 | finance.yahoo.comTRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | globenewswire.comTRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 12, 2024 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Rating Lowered to Buy at StockNews.comMay 12, 2024 | americanbankingnews.comTRACON Pharmaceuticals (TCON) to Release Quarterly Earnings on TuesdayMay 7, 2024 | globenewswire.comTRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024April 26, 2024 | money.usnews.comTRACON Pharmaceuticals IncApril 10, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation UpdateApril 10, 2024 | uk.investing.comTRACON announces 1-for-20 reverse stock splitApril 10, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 8, 2024 | marketwatch.comShares of Tracon Pharmaceuticals Tumble 22% on Reverse SplitApril 8, 2024 | finanznachrichten.deTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock SplitApril 8, 2024 | globenewswire.comTRACON Pharmaceuticals Announces Reverse Stock SplitApril 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial OutlookApril 3, 2024 | msn.comTracon Pharma drops after pivotal data for cancer drugApril 3, 2024 | finance.yahoo.comTRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as PlannedMarch 13, 2024 | markets.businessinsider.comJonesTrading Reaffirms Their Hold Rating on TRACON Pharmaceuticals (TCON)March 8, 2024 | markets.businessinsider.comBuy Rating for TRACON Pharmaceuticals on Strong Financials and Promising Clinical TrialsMarch 7, 2024 | finanznachrichten.deTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 7, 2024 | seekingalpha.comTRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call TranscriptSee More Headlines Receive TCON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today5/17/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCON CUSIPN/A CIK1394319 Webwww.traconpharma.com Phone(858) 550-0780Fax858-550-0786Employees17Year FoundedN/APrice Target and Rating Average Stock Price Target$60.00 High Stock Price Target$60.00 Low Stock Price Target$60.00 Potential Upside/Downside+4,095.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.67 Trailing P/E Ratio2.13 Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,590,000.00 Net MarginsN/A Pretax Margin13.98% Return on Equity-114.48% Return on Assets59.65% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.89 Sales & Book Value Annual Sales$12.05 million Price / Sales0.32 Cash Flow$1.51 per share Price / Cash Flow0.95 Book Value($0.66) per share Price / Book-2.17Miscellaneous Outstanding Shares2,680,000Free Float2,155,000Market Cap$3.83 million OptionableNo Data Beta1.28 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Charles P. Theuer M.D. (Age 60)Ph.D., Chairman, CEO & President Comp: $646.6kMr. Ya HuangExecutive Director of Statistical ProgrammingKey CompetitorsTC BiopharmNASDAQ:TCBPFresh Tracks TherapeuticsNASDAQ:FRTXKiromic BioPharmaNASDAQ:KRBPNanoString TechnologiesNASDAQ:NSTGQFinch Therapeutics GroupNASDAQ:FNCHView All Competitors TCON Stock Analysis - Frequently Asked Questions Should I buy or sell TRACON Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TCON shares. View TCON analyst ratings or view top-rated stocks. What is TRACON Pharmaceuticals' stock price target for 2024? 3 brokerages have issued 1 year price objectives for TRACON Pharmaceuticals' stock. Their TCON share price targets range from $60.00 to $60.00. On average, they expect the company's stock price to reach $60.00 in the next year. This suggests a possible upside of 4,095.8% from the stock's current price. View analysts price targets for TCON or view top-rated stocks among Wall Street analysts. How have TCON shares performed in 2024? TRACON Pharmaceuticals' stock was trading at $3.5020 on January 1st, 2024. Since then, TCON stock has decreased by 59.2% and is now trading at $1.43. View the best growth stocks for 2024 here. When is TRACON Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our TCON earnings forecast. How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) released its quarterly earnings results on Tuesday, May, 14th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($1.20) by $0.13. The biopharmaceutical company earned $0.10 million during the quarter. During the same quarter in the previous year, the business earned ($7.20) earnings per share. When did TRACON Pharmaceuticals' stock split? TRACON Pharmaceuticals's stock reverse split before market open on Wednesday, April 10th 2024. The 1-20 reverse split was announced on Wednesday, April 10th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 10th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX). When did TRACON Pharmaceuticals IPO? TRACON Pharmaceuticals (TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. How do I buy shares of TRACON Pharmaceuticals? Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCON) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.